• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Fat Tail Daily

Investment Ideas From the Edge of the Bell Curve

  • Menu
    • Commodities
      • Resources and Mining
      • Copper
      • Gold
      • Iron Ore
      • Lithium
      • Silver
      • Graphite
      • Rare Earths
    • Technology
      • AI
      • Bitcoin
      • Cryptocurrency
      • Energy
      • Financial Technology
      • Bio Technology
    • Market Analysis
      • Latest ASX News
      • Dividend Shares
      • ETFs
      • Stocks and Bonds
    • Macro
      • Australian Economy
      • Central Banks
      • World Markets
    • Small Caps
    • More
      • Investment Guides
      • Premium Research
      • Editors
      • About
      • Contact Us
  • Latest
  • Fat Tail Series
  • About Us
Market Analysis Latest ASX News

Althea Share Price Up on First Germany Shipment (ASX:AGH)

Like 0

By Lachlann Tierney, Wednesday, 10 February 2021

At time of writing, the share price of Althea Group Holdings Ltd [ASX:AGH] is up 10%, trading at 55 cents...

At time of writing, the share price of Althea Group Holdings Ltd [ASX:AGH] is up 10%, trading at 55 cents.

The AGH share price is moving upwards again to have another crack at the 60-cent mark as you can see below:

ASX-AGH share price movement

Source: Tradingview.com

We look at why the AGH share price is moving higher today and their most recent quarterly.

Highlights from latest AGH announcement

Here are the key bits from the company’s latest announcement:

‘• Althea has completed its first shipment of medicinal cannabis products to Germany

  • Initial shipment of 2,000 units valued at approximately $1,000,000 (EUR640,000)
  • Althea has partnered with one of the country’s leading pharmaceutical wholesalers of cannabis-based medicines, Nimbus Health GmbH, to launch the brand exclusively in Germany
  • Under Althea and Nimbus’ agreement, Althea will receive payment for products supplied to Nimbus, along with 50% of net profit
  • The German medicinal cannabis market is the largest medicinal cannabis market in Europe and health insurers typically cover the entire cost of medicinal cannabis treatments’

It appears this was the catalyst that the AGH share price needed to move higher.

Let’s take a quick look at their quarterly.

Outlook for AGH share price hinges on sales revenue, cash balance

As with any small-cap, particularly a pot stock, AGH needs sales momentum to confirm its potential.

Looking at the latest quarterly you can see the following:

  • Cash receipts for the quarter of $2.6 million, a 27% increase on the prior quarter
  • Operating cash outflow of $2.8 million
  • Cash balance of $8.9 million

Meaning that they can continue as they operate for a decent amount of time by small-cap standards before another capital raise.

Understanding the timing of capital raises is absolutely essential, especially given small-cap volatility and particularly in the world of pot stocks.

We’ve got a great resource for you too; it’s our 2021 pot stocks report which profiles three different options in the growing cannabis market after a consolidation period.

You can download that for free, right here.

Regards,

Lachlann Tierney,
For Money Morning

All advice is general advice and has not taken into account your personal circumstances.

Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

Comments

Subscribe
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments
Lachlann Tierney
Lachlann ‘Lachy’ Tierney is passionate about uncovering hidden opportunities in the microcap sector. With four years of experience as a senior equities analyst at one of Australia’s leading microcap firms, he has built a reputation for rigorous research, deep-dive due diligence, and accessible investor communications. Over this time, he has vetted seed, pre-IPO and ASX-listed companies across sectors, conducted onsite visits, and built strong relationships across the microcap space. Lachy is nearing completion of a PhD in economics at RMIT University, where his research focuses on blockchain governance and voting systems. His work is housed within the Blockchain Innovation Hub at RMIT, a leading research centre for crypto-economics and blockchain research. He holds a Master’s degree from the London School of Economics and an Honours BA in Philosophy and Politics from the University of Melbourne. Born in New York and raised in California, Lachy grew up a few blocks from biotech giant Amgen and counts among his peers various characters in the overlapping worlds of venture capital, technology and crypto. When he’s not researching microcaps, he’s most likely sweating it out in a sauna or dunking himself in cold Tasmanian water.

Lachlann’s Premium Subscriptions

Publication logo
Australian Small-Cap Investigator
Publication logo
Fat Tail Microcaps
Publication logo
James Altucher’s Early-Stage Crypto Investor Australia

Latest Articles

  • Nvidia earnings beat won’t stop the slide, but the Fed just might
    By Lachlann Tierney

    Nvidia's earnings beat won't halt market slides according to Lachlann Tierney. Fed rate cuts hold the key as debt delinquencies rise and private credit risks loom large.

  • Investment fads keep dying before I can profit from them
    By Nick Hubble

    By the time I’ve figured out how to profit from the latest government-driven investment boom, it suddenly ceases to exit. How can politicians be this fickle?

  • Bitcoin’s Rocky Descent: Why This Isn’t Winter (Yet)
    By Lachlann Tierney

    Bitcoin has plunged 24% from October's peak to a seven-month low, but Lachlann Tierney things this shakeout isn't a crypto winter yet. US regulatory support and central bank easing suggest otherwise.

Primary Sidebar

Latest Articles

  • Nvidia earnings beat won’t stop the slide, but the Fed just might
  • Investment fads keep dying before I can profit from them
  • Bitcoin’s Rocky Descent: Why This Isn’t Winter (Yet)
  • Why ‘One-Hit Wonder’ Explorers Will Burn Your Money: The Repeatability Test
  • Cassandra Goes Unheard

Footer

Fat Tail Daily Logo
YouTube
Facebook
x (formally twitter)
LinkedIn

About

Investment ideas from the edge of the bell curve.

Go beyond conventional investing strategies with unique ideas and actionable opportunities. Our expert editors deliver conviction-led insights to guide your financial journey.

Quick Links

Subscribe

About

FAQ

Terms and Conditions

Financial Services Guide

Privacy Policy

Get in Touch

Contact Us

Email: support@fattail.com.au

Phone: 1300 667 481

All advice is general in nature and has not taken into account your personal circumstances. Please seek independent financial advice regarding your own situation, or if in doubt about the suitability of an investment.

The value of any investment and the income derived from it can go down as well as up. Never invest more than you can afford to lose and keep in mind the ultimate risk is that you can lose whatever you’ve invested. While useful for detecting patterns, the past is not a guide to future performance. Some figures contained in our reports are forecasts and may not be a reliable indicator of future results. Any actual or potential gains in these reports may not include taxes, brokerage commissions, or associated fees.

Fat Tail Logo

Fat Tail Daily is brought to you by the team at Fat Tail Investment Research

Copyright © 2025 Fat Tail Daily | ACN: 117 765 009 / ABN: 33 117 765 009 / ASFL: 323 988